Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

This study is testing a new treatment for recurrent or growing brain tumors (glioblastoma and other high-grade gliomas) using engineered immune cells called CAR-NK cells. These cells are designed to seek out and destroy brain cancer cells by targeting specific proteins the tumors carry. This is an early-phase study focused on safety and early effectiveness. **You may be eligible if...** - You are aged 18–75 and have a confirmed high-grade brain tumor (grade 3 or 4) that has come back or continued growing after standard treatment - Your tumor expresses at least two specific proteins targeted by the therapy (IL13Rα2, EGFR, or B7-H3) - You are functional enough to carry out daily activities (KPS ≥ 60) - You are able to have a brain MRI - You have adequate blood, kidney, and liver function **You may NOT be eligible if...** - You have an active uncontrolled infection, or uncontrolled HIV, hepatitis B, or hepatitis C - You have a significant autoimmune disease requiring immune-suppressing drugs - You are on high-dose steroids - You received a similar gene-modified cell therapy within the past 6 months - You have uncontrolled seizures - You have had a recent heart attack or serious heart condition - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.